The study will enroll adult patients scheduled for elective surgery requiring general anesthesia. Participants will be randomly assigned to receive either HRS-9190 for Injection or Rocuronium. The primary objective is to assess the efficacy of HRS-9190 in providing adequate neuromuscular blockade for successful tracheal intubation. Secondary objectives include evaluating the onset time and duration of action following each dose, the total time adequate muscle relaxation is maintained during surgery, and the detailed pattern of neuromuscular recovery. Safety assessments will include monitoring of adverse events, vital signs, laboratory parameters, and other safety indicators throughout the study period. The hypothesis of this study is that HRS-9190 for Injection could provide effective neuromuscular relaxation, with a satisfied safety profile in the target patient population.
Able and willing to provide a written informed consent
Subjects requiring elective general anesthesia surgery
Meet specified age and body mass index (BMI) criteria
Conform to the ASA Physical Status Classification
History of significant neuromuscular, cardiovascular, respiratory, or neurological disorders
History of conditions affecting drug metabolism or anesthesia risk
Abnormal laboratory values indicating significant clinical abnormalities
Positive serology for specified infectious diseases